Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma We assessed physical and mental measures ...

The article below provides an evidence-based rationale for extending the duration of endocrine therapy in patients with ductal carcinoma in situ (DCIS) beyond the traditional 5-year mark. Findings ...

Ductal carcinoma in situ (DCIS) is a heterogeneous disease with multiple treatment options including breast-conserving surgery, the option of addition of radiation, and adjuvant endocrine therapy.

From the archives: Dr. Eileen Rakovitch talks to Anne Kingston about the misunderstood cancer and the effects of Belinda Stronach’s diagnosis Dr. Eileen Rakovitch is a breast cancer specialist and ...

A diagnosis of ductal carcinoma in situ (DCIS) might seem reassuring compared to invasive breast cancer, but recent research paints a more nuanced picture about this condition that affects roughly ...

Please provide your email address to receive an email when new articles are posted on . Women with DCIS who did not identify as white had greater reductions in mental health 2 years after treatment ...

Please provide your email address to receive an email when new articles are posted on . Results showed a lower 2-year cumulative rate of invasive ipsilateral breast cancer among patients assigned ...

January 21, 2010 — The term carcinoma in the phrase ductal carcinoma in situ (DCIS) is misleading and troubling and ought to be dropped, or at least its dropping should be considered, suggest some ...